Barclays Initiates Outperform Rating for Ligand Pharmaceuticals Amid Biopharma Royalty Aggregation Strategy
Barclays has initiated coverage of Ligand Pharmaceuticals (LGND) with an 'Outperform' rating, citing the company's shift toward biopharmaceutical royalty aggregation as a catalyst for long-term revenue growth exceeding 20%. The firm set a price target of $345 per share, representing approximately 15% upside from its closing price on September 24. Analysts at Barclays believe Ligand’s strategy to consolidate and manage royalties could unlock significant value over time. The investment bank highlighted that the company's evolving business model positions it well for sustained growth in a sector where royalty aggregation is gaining traction as an attractive asset class. This move reflects growing investor interest in companies with diversified revenue streams from biopharma partnerships, particularly those leveraging intellectual property and licensing agreements to drive returns.
Topics: Pharmaceuticals Stock Analysis